Vyome Holdings (HIND) Accumulated Expenses (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Accumulated Expenses of $590140.0 for Q1 2026, down 72.65% year-over-year from $2.2 million in Q1 2025, and down 32.23% quarter-over-quarter from $870822.0 in Q4 2025.
Vyome Holdings (HIND) Accumulated Expenses (2015 - 2026) Analysis & Trends
Vyome Holdings' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $590140.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 72.65% year-over-year to $590140.0; the TTM figure through Mar 2026 stood at $590140.0 (down 72.65% YoY), while the FY2025 annual figure was $870822.0, up 87.8% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $590140.0, down from $870822.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $5.8 million in Q2 2022, with the low at $249190.0 in Q3 2025.
- The 5-year median for Accumulated Expenses is $1.7 million (2023), against an average of $1.9 million.
- Peak annual rise in Accumulated Expenses reached 478.41% in 2022, while the deepest fall reached 89.06% in 2022.
- Vyome Holdings' Accumulated Expenses stood at $1.8 million in 2022, then dropped by 0.82% to $1.8 million in 2023, then slumped by 74.44% to $463686.0 in 2024, then surged by 87.8% to $870822.0 in 2025, then tumbled by 32.23% to $590140.0 in 2026.
- Business Quant data shows HIND's Accumulated Expenses at $590140.0 in Q1 2026, $870822.0 in Q4 2025, and $249190.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 517,335.00 |
| Mar 31, 2026 | 590,140.00 |
| Dec 31, 2025 | 870,822.00 |
| Sep 30, 2025 | 249,190.00 |
| Jun 30, 2025 | 1.59 Mn |
| Mar 31, 2025 | 2.16 Mn |
| Dec 31, 2024 | 463,686.00 |
| Sep 30, 2024 | 702,000.00 |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 602,000.00 |
| Dec 31, 2023 | 1.81 Mn |
| Sep 30, 2023 | 2.73 Mn |
| Jun 30, 2023 | 1.15 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 4.87 Mn |
| Jun 30, 2022 | 5.83 Mn |
| Mar 31, 2022 | 3.48 Mn |
| Dec 31, 2021 | 3.37 Mn |
| Sep 30, 2021 | 1.24 Mn |